Overview

An Open-Label Extension Study to Evaluate the Safety and Tolerability of RWJ 333369 as Adjunctive Therapy in Patients 16 Years and Older With Partial Onset Seizures.

Status:
Completed

Trial end date:
2010-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this open-label extension study is to demonstrate that RWJ-333369 is safe as long-term add-on treatment of partial onset seizures.

Phase:

Phase 3

Details

Lead Sponsor:

SK Life Science
SK Life Science, Inc.